Assessing finasteride‐associated sexual dysfunction using theFAERSdatabase
Authors:
- 16 March 2017
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (6) , 1069-1075
Abstract
Background: Postmarketing reports suggest that finasteride causes sexual dysfunction despite a low incidence reported in clinical trials. Therefore, the extent of risk remains unknown.Objective: To determine whether the risk of sexual dysfunction is higher among individuals treated with finasteride compared to a baseline risk for all other drugs using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods: A case by non‐case disproportionality approach was used whereby a reporting odds ratio (ROR) with 95% confidence interval (CI) was calculated. The National Ambulatory Medical Care Survey (NAMCS) was used to confirm results.Results: A significant disproportionality in reporting of sexual dysfunction with the use of finasteride was observed whether finasteride was indicated for hair loss (ROR = 138.17, 95% CI: 133.13, 143.4), prostatic hyperplasia (ROR = 93.88, 95% CI: 84.62, 104.16) or any indication (ROR = 173.18, 95% CI: 171.08, 175.31). When these results were stratified by age, disproportionality was strongest at 31–45 years.Conclusion: Use of finasteride has led to an increase in reports of sexual dysfunction where it is believed to be the primary suspect.Keywords
This publication has 32 references indexed in Scilit:
- Data Mining of the Public Version of the FDA Adverse Event Reporting SystemInternational Journal of Medical Sciences, 2013
- Persistent Sexual Side Effects of Finasteride for Male Pattern Hair LossThe Journal of Sexual Medicine, 2011
- Finasteride 5 mg and Sexual Side Effects: How Many of these are Related to a Nocebo Phenomenon?The Journal of Sexual Medicine, 2007
- Assessment of sexual dysfunction in patients with benign prostatic hyperplasiaBJU International, 2006
- The psychosocial impact of hair loss among men: a multinational European studyCurrent Medical Research and Opinion, 2005
- A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis)BJU International, 2004
- The effect of finasteride in men with benign prostatic hyperplasiaJournal of Urology, 2002
- Finasteride in the treatment of men with androgenetic alopeciaJournal of the American Academy of Dermatology, 1998
- Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy menThe Journal of Clinical Endocrinology & Metabolism, 1995
- Psychological effects of androgenetic alopecia on women: Comparisons with balding men and with female control subjectsJournal of the American Academy of Dermatology, 1993